JUN 10, 2020 7:14 AM PDT

FDA Approves New Antibiotic for Hospital-Acquired Pneumonia

WRITTEN BY: Annie Lennon

The US Food and Drug Administration (FDA) has approved Recarbrio, an antibiotic drug created by pharmaceutical company Merck, to treat different varieties of bacterial pneumonia typically contracted in hospitals. 

Recarbrio is a mixture of antibiotic imipenem-cilastatin and the beta-lactamase inhibitor, relebactam, used to increase the efficiency of the active antibiotic. The drug has previously been approved to treat patients with complicated urinary tract infections and intra-abdominal infections who have limited or no other treatment options. 

Now, the agency has approved the drug for usage against hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by gram-negative microorganisms in people over 18 years old. 

Patients usually contract HABP and VABP types of pneumonia in hospital settings. Symptoms include fever, chills, cough, chest pain, and an increased need for oxygen. 

To assess the safety of the drug for HABP/VABP, researchers conducted a randomized, controlled clinical trial involving 535 with either condition. While 266 patients were treated with Recarbrio intravenously, the remaining 269 were treated with piperacillin-tazobactam, another drug with antibacterial properties. 

In the end, the researchers found that while 21.3% of those on piperacillin-tazobactam died before Day 28 of the study, the same was true for only 15.9% of patients on Recarbrio. Meanwhile, the clinical response at early follow-up was 61% for those on Recarbrio, whereas just 55.8% for the control drug. 

Negative side effects for Recarbrio included anemia, diarrhea, hypokalemia (low potassium levels), and hyponatremia (low sodium levels). Before qualifying for treatment with Recarbrio, patients are urged to share information on previous hypersensitivity reactions to allergens that could hamper treatment. 

The FDA also notes that the drug should not be used in patients prone to seizures and other nervous system disorders. As with almost all antibacterial drugs, Recarbrio leads to Clostridioides difficile-associated diarrhea and may range from mild diarrhea to fatal colitis. 


Sources: FDA, Yahoo News, Drug Topics

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
SEP 21, 2020
Drug Discovery & Development
WHO Endorses Clinical Trials for Herbal Medicines to Treat COVID-19
SEP 21, 2020
WHO Endorses Clinical Trials for Herbal Medicines to Treat COVID-19
The World Health Organization has endorsed a protocol to put African herbal medicines through clinical trials as possibl ...
NOV 02, 2020
Drug Discovery & Development
Beetroot Peptide Shows Promise in Treating Inflammatory Diseases
NOV 02, 2020
Beetroot Peptide Shows Promise in Treating Inflammatory Diseases
Researchers from the Medical Univesity of Vienna in Austria have found that a peptide (a small protein molecule) found i ...
NOV 05, 2020
Immunology
Awakening Ancient DNA to Kill Cancer
NOV 05, 2020
Awakening Ancient DNA to Kill Cancer
In a recent study published in Nature, scientists from the University of Toronto described the discovery of ancient DNA ...
NOV 11, 2020
Cancer
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
NOV 11, 2020
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
Amongst the most common targets of anti-cancer drugs are small regulatory molecules called cyclin-dependent kinases (CDK ...
NOV 09, 2020
Drug Discovery & Development
COVID-19 Vaccine by Pfizer More than 90% Effective
NOV 09, 2020
COVID-19 Vaccine by Pfizer More than 90% Effective
A preliminary analysis of Pfizer and BioNTech's COVID-19 vaccine shows that it can prevent over 90% of people from c ...
NOV 18, 2020
Drug Discovery & Development
Hepatitis C Drugs May Be Involved Coronavirus Treatment
NOV 18, 2020
Hepatitis C Drugs May Be Involved Coronavirus Treatment
At the present moment, there are no inhibitors that target protease activity of the novel SARS-CoV-2. The main proteases ...
Loading Comments...